
Need information?
CONTACT US
ARGENE® Respiratory range
A range of real-time PCR kits for accurate simultaneous detection of infectious agents involved in respiratory diseases
- “à la carte” diagnosis thanks to modular duplex PCR solution
- Ready-to-use kits including positive and negative controls
- CE-IVD on all major extraction platforms and real-time PCR systems
Do you need more information?
ARGENE® Respiratory menu
What could be easier? The ARGENE® Respiratory range of real-time PCR kits is your solution for detection of more than 35 respiratory pathogens involved in respiratory illness, thanks to its full menu:
- Influenza A/B R-GENE®
- RSV/hMPV R-GENE®
- Rhino&EV/Cc R-GENE®
- AdV/hBoV R-GENE®
- Chla/Myco pneumo R-GENE®
- HCoV/HPIV R-GENE®
- Legio pneumo/Cc R-GENE®
- BORDETELLA R-GENE®
- Bordetella parapertussis R-GENE®
- SARS-COV-2 RESPI R-GENE®
- COVID-19 R-GENE®
ARGENE® Respiratory advantages
Acute Respiratory Infections (ARI) account for an estimated 75% of all acute morbidities in industrialized countries and continue to be the leading cause of acute illness worldwide. The most serious and potentially life-threatening pneumopathies occur mainly in young children, the elderly, and immunocompromised or weakened individuals (such as those with chronic disease, cancer, or in intensive care units). The vast majority of respiratory illnesses are caused by bacteria and viruses. Since symptomatologies are similar, appropriate diagnostic testing is essential to identifying infectious agents.
Optimized detection of infectious agents is necessary to ensure optimal patient management and to prevent the spread of infection.
- Modular multiplex solution
- Adopt a targeted diagnostic strategy with an “à la carte” menu
- Choose which pathogens to test depending on the season
- Allow the diagnosis of co-infections
- Sensitive and reproducible
- Reliable measurement of infectious agents involved in respiratory diseases
- All controls included (positive and negative control, cell control)
- Standardized
- Uniform protocol for DNA & RNA targets
- Parallel processing with the pathogens detected with the ARGENE® Respiratory range.
- Harmonized test profiles for multiple assays in one run
- Flexible
- Validated for use with various respiratory samples types
- Compatible with automated sample preparation systems such as NUCLISENS® easyMAG® and EMAG®, as well as user-friendly assay setup techniques such as ESTREAM® liquid handling system
- Qualified with the major real-time PCR platforms
A complete kit with all you need
ARGENE® Respiratory kits are ready-to-use molecular kits for the detection of pathogens by real-time PCR after viral DNA & RNA extraction. This 5’ nuclease-based Taqman technology amplifies and simultaneously detects a specific region of the pathogen genome.
- Cell control to validate the sample quality for some kits
- Negative and Pathogen-specific Positive controls
- Includes all necessary reagents optimized to detect pathogens for in vitro diagnostic use
Straightforward procedure
Using ARGENE® Respiratory range of assays is straightforward and simple. Just add the extracted DNA or RNA sample to the ready-to-use PCR master mix chosen and start the reaction on the appropriate Real-Time PCR thermocycler, following optimized cycling program described in the “Instructions For Use”.
BIOMERIEUX, the blue logo, ARGENE®, R-GENE®, EMAG® and NUCLISENS® easyMAG® are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies. Any other name or trademark is the property of its respective owner.
Influenza A/B R-GENE®
Influenza A/B R-GENE® (71-040) | |
---|---|
Principle of the test | Duplex amplification and detection of Influenza A and Influenza B |
Ordering information | Reference 71-040 : Influenza A/B R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | Influenza A: M gene Influenza B: M gene |
Specimen* | Respiratory samples |
Controls included | Positive control, negative control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Automated Extraction platform* | EMAG® NUCLISENS® easyMAG® QIAsymphony SP |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe |
*Please enquire
RSV/hMPV R-GENE®
RSV/hMPV R-GENE® (71-041) | |
---|---|
Principle of the test | Duplex amplification and detection of RSV (A&B) and hMPV (A&B) |
Ordering information | Reference 71-041: RSV/hMPV R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | RSV: N gene hMPV: M gene |
Specimen* | Respiratory samples |
Controls included | Positive control, negative control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Automated Extraction platform | EMAG® NUCLISENS® easyMAG® QIAsymphony SP |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe |
*Please enquire
Rhino&EV/Cc R-GENE®
Rhino&EV/Cc R-GENE® (71-042) | |
---|---|
Principle of the test | Duplex amplification and detection of Rhinovirus (A,B,C) & Enterovirus (A,B,C,D) and cellular control |
Ordering information | Reference 71-042: Rhino&EV/Cc R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | Rhinovirus & Enterovirus: 5’ non coding region Cell control: HPRT1 gene |
Specimen* | Respiratory samples (nasopharyngeal aspiration, nasal swab, nasal lavage, bronchoalveolar fluid) |
Controls included | Positive control, negative control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Automated Extraction platform | EMAG® NUCLISENS® easyMAG® QIAsymphony SP |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe |
*Please enquire
AdV/HBoV R-GENE®
AdV/hBoV R-GENE® (71-043) | |
---|---|
Principle of the test | Duplex amplification and detection of Adenovirus (A,B,C,D,E,F,G) and Bocavirus (hBoV 1,2,3,4) |
Ordering information | Reference 71-043 : AdV/hBoV R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | Adenovirus: HEXON gene Bocavirus: NS1 or VP1 gene |
Specimen* | Respiratory samples (nasopharyngeal aspiration, nasal swab, nasal lavage, bronchoalveolar fluid) |
Controls included | Positive control, negative control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Automated Extraction platform | EMAG® NUCLISENS® easyMAG® QIAsymphony SP |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe |
*Please enquire
Chla/Myco pneumo R-GENE®
Chla/Myco pneumo R-GENE® (71-044) | |
---|---|
Principle of the test | Duplex amplification and detection of Chlamydia pneumoniae and Mycoplasma pneumoniae |
Ordering information | Reference 71-044 : Chla/Myco pneumo R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | Chlamydia pneumoniae: OMP2 gene Mycoplasma pneumoniae: P1 gene |
Specimen* | Respiratory samples (nasopharyngeal aspiration, nasal swab, nasal lavage, bronchoalveolar fluid) |
Controls included | Positive control, negative control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Automated Extraction platform | EMAG® NUCLISENS® easyMAG® QIAsymphony SP |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe |
*Please enquire
HCoV/HPIV R-GENE®
HCoV/HPIV R-GENE® (71-045) | |
---|---|
Principle of the test | Duplex detection of both human Coronaviruses (NL63, OC43, HKU1, 229E) and Parainfluenza viruses (HPIV1, HPIV 2, HPIV 3, HPIV4). |
Ordering information | Reference 71-045 : HCoV/HPIV R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | HCoV: N gene HPIV: N gene |
Specimen* | Respiratory samples |
Controls included | Positive control, negative control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Automated Extraction platform | EMAG® NUCLISENS® easyMAG® QIAsymphony SP |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe |
*Please enquire
Legio pneumo /Cc R-GENE®
Legio pneumo R-GENE® (71-046) | |
---|---|
Principle of the test | Duplex amplification and detection of Legionella pneumophila (15 serogroups, including serogroup 1) and a cellular control |
Ordering information | Reference 71-046 : Legio pneumo/Cc R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | Legionella pneumophila : MIP gene Cell control: HPRT1 gene |
Specimen | Bronchoalveolar lavage, tracheo-bronchial aspirates and sputum |
Controls included | Positive control, negative control, cell control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Automated Extraction platform | EMAG® NUCLISENS® easyMAG® QIAsymphony SP |
Validated Amplification platform* |
ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96
|
Status | For in vitro diagnostic use, CE marking in Europe |
*Please enquire
BORDETELLA R-GENE® (69-011B)
BORDETELLA R-GENE® (69-011B) | |
---|---|
Principle of the test | Genomic detection of Bordetella pertussis |
Ordering information | Reference 69-011B: BORDETELLA R-GENE® kit |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | IS481 region |
Specimen* | Nasopharyngeal aspirations and expectorations |
Controls included | Extraction + Inhibition control, Negative control, Positive Control |
Results within | 75 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Extraction platform* | EMAG® NUCLISENS easyMAG® |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe- Please enquire |
Bordetella parapertussis R-GENE (71-012)
Bordetella parapertussis R-GENE (71-012) | |
---|---|
Principle of the test | Genomic detection of Bordetella parapertussis |
Ordering information | Reference 71-012: Bordetella parapertussis R-GENE kit |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | IS1001 region |
Specimen* | Nasopharyngeal aspirations and expectorations |
Controls included | Extraction + Inhibition control, Negative control, Positive control |
Results within | 75 minutes (extraction step not included) |
Reporting unit | Qualitative test |
Number of tests | 60 tests |
Storage conditions | -15°C/-31°C |
Validated Extraction platform* | EMAG® NUCLISENS easyMAG® |
Validated Amplification platform* | ABI7500 Fast, ABI 7500 Fast Dx LightCycler 480 System II Rotor-Gene Q CFX96 |
Status | For in vitro diagnostic use, CE marking in Europe- Please inquire |
* please enquire
SARS-COV-2 RESPI R-GENE® (423732)
SARS-COV-2 RESPI R-GENE® (423732) | ||
---|---|---|
Ordering information | SARS-COV-2 RESPI R-GENE® - Ref.: 423732 | |
Kit content |
All included Positive controls, Negative Control, Cell control |
|
Gene targets |
PCR1 (96 tests) SARS-CoV-2 : N & RdRp (670 nm) Influenza A : M gene (530 nm) Influenza B : M gene (560 nm) Cell control : HPRT1 (610 nm) |
PCR2 (96 tests) RSV A/B : N gene (530 nm) hMPV A/B : M gene (560 nm) |
Number of tests | 96 tests | |
Validated Specimen | Nasopharyngeal swabs | |
Validated Platforms | Extraction | Amplification |
|
|
|
Shelf Life | 12 months at launch | |
Regulatory Status | For In vitro Diagnostic use (CE-IVD) | |
Storage conditions | -15°C / -31°C |
COVID-19 R-GENE® (424017) - Real Time Detection kit | |
---|---|
Principle of the test | Genomic detection of SARS-CoV-2 |
Ordering information | Reference: 424017 Designation: COVID-19 R-GENE® - Real Time Detection kit |
Technology | Real-Time PCR / 5’ nuclease technology |
PCR design & Gene target |
|
Specimen |
|
Controls included | Negative Control, Positive Control, Endogenous Internal Control |
Number of tests | 96 tests |
Storage conditions | -15°C/-31°C |
Extraction platform |
|
Amplification platform |
|
Status | For In vitro Diagnostic use (CE-IVD) |
Fast facts on Respiratory Pathogens
What are Respiratory Pathogens?
The vast majority of respiratory illnesses are caused by viruses and bacteria. In both children and adults, acute respiratory infections (ARI) are most frequently due to infections with Influenza A and B viruses, Parainfluenza viruses 1, 2 and 3, Respiratory Syncytial Virus (RSV A and B), Adenoviruses and Rhinoviruses. Others pathogens such as Coronaviruses, Bocaviruses, Enteroviruses, Parainfluenza 4, human Metapneumovirus, Mycoplasma pneumonia, Chlamydia pneumoniae, Legionella pneumophila, Bordetella pertussis and Bordetella parapertussis also infect the respiratory tract and can cause various diseases from mild self-limiting upper respiratory infections to potentially threatening pneumonia.
Who is most at risk?
Anyone can become infected and ill with these respiratory pathogens. However, young children, the elderly, immunocompromised or weakened individuals (including those with chronic disease, cancer, or in intensive care) are most likely to suffer serious and potentially life-threatening pneumopathies.
What are the benefits of Respiratory pathogens molecular testing?
Clinical symptoms for different respiratory illnesses are similar so in vitro diagnostic molecular methods are necessary to determine the causative agents. Early, rapid and specific detection of the virus or bacteria involved using real-time PCR methods is essential to provide patient-tailored therapy for better outcomes. An accurate diagnosis will also help to control outbreaks, reduce potential antibiotic resistance and facilitate a more rapid patient recovery.
ARGENE® Respiratory: PUBLICATIONS & POSTERS
Infections respiratoires aigües : étude comparative des trousses d’amplification génique en temps réel respiratory multi well system r-gene de BioMérieux et Respiratory pathogens 21 de Fast Track diagnostics.
Trombert-Paolantoni S., Hedbaut E., Clairet V
RICAI 2015
Pattern of Respiratory Pathogen Nasal Colonization in the first year of life in Healthy Infants and Infants with Cystic Fibrosis
Insa Korten et al.
Poster ESCV 2016
BioMérieux molecular workflow : solution for ARGENE® product range automation
Bourdin Jérôme; Levillain Erwan; Bes Jérôme; Guy Michel; Margry Pascal; Bufflier Emmanuel; Chini Giorgio; Pradier Nicolas; Magro Stephane; Brengel-Pesce Karen
Poster ESCV 2014
Please consult your local bioMérieux representative for product availability in your country
COMPLETE YOUR SOLUTION
- Legal Notice
- Privacy
- Cookie Policy
- Contact
- Sitemap
- Copyright 2022 bioMérieux SA